Premium
SSRIs and venlafaxine show no major risk of cardiac birth defects
Publication year - 2015
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30068
Subject(s) - venlafaxine , confounding , medicine , antidepressant , in utero , sibling , cohort , pregnancy , cohort study , population , pediatrics , obstetrics , psychiatry , environmental health , psychology , anxiety , fetus , developmental psychology , biology , genetics
A population‐based cohort study that included births in five nations found no significant increase in the prevalence of cardiac birth defects in children born to mothers who took selective serotonin reuptake inhibitors (SSRIs) or venlafaxine during pregnancy. The study accounted for numerous potential confounding factors, including by using sibling‐controlled analyses to examine families in which one child was exposed to an antidepressant in utero and the other was not.